Page last updated: 2024-08-03 00:00:03

santalol

Description

santalol: combination of alpha and beta isomers [MeSH]

Cross-References

ID SourceID
PubMed CID12315259
SCHEMBL ID10980513
MeSH IDM0127277

Synonyms (12)

Synonym
11031-45-1
santalol
2-penten-1-ol, 2-methyl-5-[(1s,2r,4r)-2-methyl-3-methylenebicyclo[2.2.1]hept-2-yl]-, (2z)-
2-methyl-5-((1s,2s,4r)-2-methyl-3-methylenebicyclo[2.2.1]heptan-2-yl)pent-2-en-1-ol
SCHEMBL10980513
(e)-2-methyl-5-[(1s,2s,4r)-2-methyl-3-methylidene-2-bicyclo[2.2.1]heptanyl]pent-2-en-1-ol
A894911
73890-74-1
(E)-2-METHYL-5-((1S,2S,4R)-2-METHYL-3-METHYLENEBICYCLO[2.2.1]HEPTAN-2-YL)PENT-2-EN-1-OL
(2e)-2-methyl-5-[(1s,2s,4r)-2-methyl-3-methylidenebicyclo[2.2.1]heptan-2-yl]pent-2-en-1-ol
DTXSID601121647
rel-(2e)-2-methyl-5-[(1r,2r,4s)-2-methyl-3-methylenebicyclo[2.2.1]hept-2-yl]-2-penten-1-ol

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (4.84)18.7374
1990's1 (1.61)18.2507
2000's14 (22.58)29.6817
2010's37 (59.68)24.3611
2020's7 (11.29)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.49%)5.53%
Reviews5 (7.46%)6.00%
Case Studies1 (1.49%)4.05%
Observational0 (0.00%)0.25%
Other60 (89.55%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
acetic acidmonocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
2000200024.0low001000
adenine6-aminopurines;
purine nucleobase
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
202120213.0low000001
1-anilino-8-naphthalenesulfonateaminonaphthalene;
naphthalenesulfonic acid
fluorescent probe2014201410.0low000010
kojic acid4-pyranones;
enol;
primary alcohol
Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
2013201311.0low000010
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-onechromones;
morpholines;
organochlorine compound
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
201520159.0low000010
alloxanpyrimidonehyperglycemic agent;
metabolite
2013201311.0low000010
9,10-dimethyl-1,2-benzanthraceneortho-fused polycyclic arene;
tetraphenes
carcinogenic agent2005201116.7low000210
galactoseD-galactose;
galactopyranose
Escherichia coli metabolite;
mouse metabolite
2013201311.0low000010
colchicinealkaloid;
colchicine
anti-inflammatory agent;
gout suppressant;
mutagen
201520159.0low000010
cycloheximideantibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol
anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
2005200519.0low000100
musk ambrette (artificial)C-nitro compound1987198737.0low010000
limonenecycloalkene;
p-menthadiene
human metabolite2012201212.0low000010
silver nitrateinorganic nitrate salt;
silver salt
astringent2012201212.0low000010
3-carenemonoterpene1962196262.0low010000
tetradecanoylphorbol acetateacetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester
antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
2011201113.0low000010
oseltamiviracetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound
antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
2012201212.0low000010
magnololbiphenyls2013201311.0low000010
honokiolbiphenyls2013201311.0low000010
dehydrocostus lactonegamma-lactone;
guaiane sesquiterpenoid;
organic heterotricyclic compound;
sesquiterpene lactone
antimycobacterial drug;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 2 inhibitor;
metabolite;
trypanocidal drug
2000200024.0low001000
caranecarbobicyclic compound;
monoterpene;
terpenoid fundamental parent
1962196262.0high010000
alpha-santalene1962202325.0high010011
2'-hydroxy-2,4,4,7,4'-pentamethylflavan201720177.0high000010
mevalonic acid3,5-dihydroxy-3-methylpentanoic acid201820186.0low000010
lignans2013201311.0low000010
betadexcyclodextrin201520159.0low000010
farnesolfarnesolplant metabolite201520178.0low000020
squalenetriterpenehuman metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
2012201212.0low000010
sesquiterpenes1962202314.1high13314361
curcuminaromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol
anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
2010201014.0low000100
bilirubinbiladienes;
dicarboxylic acid
antioxidant;
human metabolite;
mouse metabolite
2013201311.0low000010
humulenealpha-humulene1962196262.0low010000
costunolide2000200024.0low001000
bisabolol201520159.0low000020
hinesol2000200024.0low001000
cytochrome c-t2005200519.0low000100
chlorophyll achlorophyll;
methyl ester
cofactor202320231.0low000001
methyl jasmonate202320231.0low000001
warfarinbenzenes;
hydroxycoumarin;
methyl ketone
1997199727.0low001000
3-methyladenine202120213.0low000001
dinitrobenzenes1987198737.0low010000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Ache02000200024.0low001000
Alloxan Diabetes02013201311.0low000010
Angiogenesis, Pathologic02013201311.0low000010
Benign Neoplasms0201920195.0low000010
Body Weight02013201311.0low000010
Breast Cancer0201320188.2low000040
Breast Neoplasms0201320188.2low000040
Cancer of Mouth0201520159.0low000010
Cancer of Prostate0201220217.5low000031
Cancer of Skin02005201316.0low000320
Cancer, Radiation-Induced02006201314.5low000110
Carcinoma02005200519.0low000100
Carcinoma, Anaplastic02005200519.0low000100
Contact Dermatitis01987198737.0low010000
Dermatitis, Contact01987198737.0low010000
Disease Models, Animal02005200718.0low000200
Incontinentia Pigmenti Achromians01987198737.0low010000
Inflammation0201920195.0low000010
Innate Inflammatory Response0201920195.0low000010
Long Sleeper Syndrome02007200717.0low000100
Mouth Neoplasms0201520159.0low000010
Neoplasms0201920195.0low000010
Neuroblastoma0202320231.0low000001
Pain02000200024.0low001000
Papilloma02005200519.0low000100
Papilloma, Squamous Cell02005200519.0low000100
Prostatic Neoplasms0201220217.5low000031
Skin Neoplasms02005201316.0low000320
Sleep Wake Disorders02007200717.0low000100
Vitiligo02010201014.0low000100

Safety/Toxicity (1)

ArticleYear
α- and β-Santalols Directly Interact with Tubulin and Cause Mitotic Arrest and Cytotoxicity in Oral Cancer Cells.
Journal of natural products, , Jun-26, Volume: 78, Issue:6
2015